



Prescription drugs for affordability review (approved by the board on Dec. 13, 2023)

Proprietary name(s)	Non-proprietary name
Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab
Entyvio	Vedolizumab
Genvoya	Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide
Inflectra	Infliximab-dyyb
Ocrevus	Ocrelizumab
Rybelsus / Ozempic	Semaglutide
Shingrix	Zoster Vaccine Recombinant Adjuvanted
Skyrizi / Skyrizi Pen	Risankizumab-rzaa
Tremfya	Guselkumab
Triumeq / Triumeq PD	Abacavir-Dolutegravir-Lamivudine
Trulicity	Dulaglutide
Vyvanse	Lisdexamfetamine Dimesylate

Insulin products for affordability review (approved by the board on Dec. 13, 2023)

Insulin type	Proprietary name(s)	Non-proprietary name
Long-Acting	Tresiba	Insulin Degludec
Long-Acting	Tresiba FlexTouch	Insulin Degludec
Short-Acting	Humulin R U-500 KwikPen	Insulin Regular (Human)